# Highly potent depeptidyl peptidase IV inhibitors derived from Alogliptin with the pharmacophore hybridization and lead optimization

Hui Xieä, Lili Zenga, Shaogao Zenga, Xin Lua, Xin Zhaoa, Guicheng Zhanga, Zhengchao Tua, Hongjiang ${ \mathrm { X u } } ^ { \mathrm { b } }$ , Ling Yangb, Xiquan Zhangb, Wenhui Hua c\*

"Guangzhou InstitutesofiomedicineandHealth,ChineseAcademyofSience,90KaiyuanAvenue,GuangzhouSciencePark, Guangzhou,510530,China   
bJiangsuChia-TaiTianqingPharmaceuticalCo.Ltd,No.8JulongNorthRd.XinpuLianyungangJiangsu,222O6,China. ‘State Key Laboratory of Respiratory Disease,Guangzhou,5l0l20,China.

# GRAFICABSTRACT

![](images/29101d477365b1652cb91265f1902e6223b569223c410362f9f8af7df8b2e47c.jpg)

# ABSTRACT

The structural superposition of DPP-IV complex with Alogliptin and Linagliptin displayed a similar binding mode.The butynyl of Linagliptin and cyanobenzyl of Alogliptin occupy the S1 pocket which therefore could be mutually switched. Thus a pharmacophore hybridization of Alogliptin was initiated and led to a novel DPP-IV inhibitor 61.Though it did not exhibit desired activity $( \mathrm { I C } _ { 5 0 } { = } 0 . 2 ~ \mu \mathrm { M } )$ ,the butynyl compound acts as a lead compound triggered a following structural optimization.A novel series of potent DPP-IV inhibitors represented by compound 77 $( \mathrm { I C } _ { 5 0 } { = } 0 . 3 6 \ \mathrm { n M } )$ were obtained with a robust pharmacokinetic profile and better in vitro and in vivo efficacy than Alogliptin.

# KEYWORDS

DPP-IV inhibitor, type 2 diabetes,superposition, pharmacophore hybridization, in vivo

# 1．Introduction

Type 2 diabetes (T2D,formerly referrd to as non-insulin-dependent or adult-onset diabetes)results from the body's ineffective use of insulin and comprises over $9 0 \%$ of diabetes patients.With more than 371 million people affected worldwide in2Ol2,diabetes is abig social burden with more than471biliondolars coston itshealthcare. Insuficient blood glucose control leads to multi-system complications with severe harm to T2D patients‘lives. However traditional treatments,such as secretagogues and insulin sensitizer,are usually associated with undesired side effcts like hypoglycemia,edema,body weight gain.Thus,more and persistent efort should be paid to meet the medical need of T2D and relief its global burden1.

Glucose like peptidase-1(GLP-1） is an important incretin which contributes to the increase of insulin secretion and sensitivity, $\beta$ cell mass,and satiety,as well as the reduction of glucagon secretion and gastric emptying. Yet GLP-1 is rapidly truncated by dipeptidyl peptidase IV(DPP-IV)and lost its function in the normal physical condition2.Thus inhibition of DPP-IVcould effectively maintain the GLP-1 function and control glucose level.DPP-IV inhibitors gradually became the major intervention for type 2 diabetics represented by marketed drugs Sitagliptin $\mathbf { 1 } ^ { 3 }$ ，Vildaglipin $2 ^ { 4 }$ ，Saxagliptin $3 ^ { 5 }$ ，Alogliptin $4 ^ { 6 }$ ，Linagliptin ${ \pmb 5 } ^ { 7 }$ ，Gemigliptin $\mathbf { 6 } ^ { 8 }$ ，and Teneligliptin ${ \boldsymbol { 7 } } ^ { 9 }$ (Figure 1). Compared to conventional treatments,DPP-IV inhibitors_ have demonstrated themselves as of good patient compliance,reduced risks of hypoglycemia, and less side effect10.

![](images/1b9886928e1645bc70de017c03668e0daf7db4ae48bf8950ac4453fc1066c290.jpg)  
Figure1.Marketed DPP-IV inhibitors.

Inour previous work， we successfully demonstrated the replaceability among pyrimidine dione, thienopryimidine,and pyrrolopyrimidine scaffold with similar DPP-IV inhibitory activity based on scaffold hopping strategyl1.Later we went on hybridizing butynyl pharmacophore into our pyrolopyrimidine scaffold and generated another potent DPP-IV inhibitor with nano malar $\mathrm { I C } _ { 5 0 }$ valuel2. At the same time,we noticed the similar location of butynyland cyanobenzyl in DPP-IV enzyme in a structure superposition of DPP-IV enzymes complex with Alogliptin and Linagliptin. Therefore we applied the pharmacophore hybridization directly to pyrimidine dione scaffold of Alogliptin and replaced cyanobenzyl with butynyl as our another novel hit (61, $\mathrm { I C } _ { 5 0 } { = } 1 9 8 \ \mathrm { n M }$ ） Herein we tried to present the generation process of compound 61 and its further optimization,as well as the pharmacological evaluations on the representative compound 77.

# 2. Chemistry

The synthesis of compounds 1la-o is outlined in Scheme 1.Alkylation of 8 with 1-bromo-2-butyne provided precursor 9.Compounds 10a-o were obtained by the N-alkylation of 9. Compounds 1la-o were obtained by the replacement of the chloro group with a 3-(R)-aminopiperidinyl group.

![](images/34f5984b63ffe47488cc97e96155360c9baf85bc56bf0f1e65d7693625f7d92a.jpg)

Scheme 1.Synthesis of compounds1la-o.Reagents:(a) 1-bromo-2-butyne,DIEA,DMF,rt; (b) $\mathrm { R C H } _ { 2 } X$ 1 $\mathrm { \nabla { X } = \mathrm { C l } }$ ,Br,I),NaH,LiBr, DMF;(c) 3-(R)-aminopiperidine, $\mathrm { \Delta N a H C O _ { 3 } }$ $1 2 0 ^ { \circ } \mathrm { C }$ $\mathrm { \Delta N a H C O _ { 3 } }$ ,EtOH.

# 3.Results and discussion

# 3.1.Generation of hit compound 61.

Our previous work on DPP-IV inhibitors revealed that the cyanobenzyl should be freely changeable with butynyl if the 3-(R)-aminopiperidinyl group was stillpresent12. In addition, we superimposed the crystal structures ofDPP-4 complex with Alogliptin and Linagliptin13 in Discovery Studio 3.0 (Accelrys, San Diego, CA). We observed the butynyl and cyanobenzyl laid in the same S1 pocket of the enzyme which may indicate the replaceability of them. In the other hand, we had proved the scaffold hopping feasibility between xanthine and pyrimidine dione scaffold. As a result, compound 61 was immediately generated by replacing cyanobenzyl with butynyl directly on Alogliptin. Compound 61 showed a decreased activity with $\mathrm { I C } _ { 5 0 }$ of $1 9 8 \mathrm { \ n M }$ ，which may partially due to the lack of interaction between butynyl and Arg 125 than that within cyanobenzyl. Yet compound 61 was stillchose to go on the follwed optimization for its acceptable activity and selectivity against DPP-IV.

![](images/70caca1fba341c824099bac526a365502aeae9d54622fb4a8819d6de3c6eb63b.jpg)  
Figure 2. Structure superposition between crystal structures of DPP4 bingding Alogliptin (PDB ID. 3G0B, blue and yellow) and Linagliptin (PDB ID. 2RGU, grey and red).

# 3.2.N-3 position variations on compound 61.

Though with decreased activity,compound 61 has large space to improve in this issue. Compared with crystal structure of Linagliptin, variations on pyrimidine dione of 61 could easily provide another interaction site with proper substituent.Thus substitutions variation was conducted at N-3 position of compound 61 to evaluate their effecton DPP-IV inhibitory activity.Data are listed in Table 1.Inhibitionon DPP-8/9 has been frequently associated with toxicity inanimal studies.Thus the inhibitoryactivityagainst DPP-8/9 were concurrently evaluated.Butynyl substituted pyrimidine dione scafold generally displayed very good selectivity in vitro and with low risk of toxicity14. Generally substitutions with proper size (65-66 vs.69-71)and stereo direction (68 vs. 69-71) had a better affinity with DPP-IV enzyme.Compound 67 with pyrimidinyl has $\mathrm { I C } _ { 5 0 }$ value of $3 . 4 ~ \mathrm { n M }$ Compound 70 has the lowest $\mathrm { I C } _ { 5 0 }$ with increase of hydrophobicity. Yet too much hydrophobicity would decrease the interaction with enzymes on the contrary (71).

Pharmacokinetic studyof 70 showed its $6 3 . 3 \%$ oral bioavailability and 4.2 hours oral half life in male Sprague Dawleyrats.The intravenous half ife was 1.76 hours.The diference between oral and intravenous half life might indicate this compound bears a possbilityof enterohepatic cycling,which contributes tothe longer half life. Fortunately 70 has litte inhibition on cytochrome P450 3A (CYP 3A, $\mathrm { I C } _ { 5 0 } { = } 9 7 . 9 ~ { \mu \mathrm { M } } ,$ , reducing the drug-drug interaction risk.As a result, compound 70 is selected as the lead compound for further optimization.

Table 1.DPP inhibitory profile of compound 65-71.   

<html><body><table><tr><td colspan="4">R NH2</td></tr><tr><td rowspan="2">No. R</td><td colspan="3">IC50</td></tr><tr><td>DPP-IV (nM)</td><td>DPP-8 (μM)</td><td>DPP-9 (μM)</td></tr><tr><td>6511b</td><td></td><td>2177.5</td><td>>100</td><td>>100</td></tr><tr><td>6611c</td><td></td><td>>10000</td><td>>100</td><td>>100</td></tr><tr><td>6711d</td><td></td><td>3.4</td><td>>100</td><td>>100</td></tr><tr><td>6911e</td><td>工2</td><td>22.0</td><td>>100</td><td>>100</td></tr><tr><td>7011f</td><td></td><td>3.1</td><td>>100</td><td>>100</td></tr><tr><td>7111g</td><td></td><td>31.3</td><td>>100</td><td>>100</td></tr></table></body></html>

Data represent means of at least two independent experiments.

# 3.3.Lead optimization on compound 70.

We evaluated different single substitutions on quinoline of lead compound 70.Table 2 summarizes the inhibitory properties.From compound 72 to76，small and electronic donor groups provided beter DPP-IV inhibitoryactivityat6 position.We believe that the R partofthis structure should interact withtheenzyme mainly by $\pi { - } \pi$ stacking.Thus the effect of electronic effect accounts for more effect than steric hindrance (76).Based on the data，substitutions preference showed a 7 position> 4 position>6 position sequence.Among them, 7-chloroquinolinylmethly substituted compound 77 displayed highly potent and selective property.Although variations on 7 position were not so sufficient, electronic effect was still slightly over steric hindrance.

Table 2.Inhibitory profile of compound 72-79.   

<html><body><table><tr><td colspan="6">NH2</td></tr><tr><td rowspan="2">No.</td><td rowspan="2">R</td><td colspan="4">IC50</td></tr><tr><td>DPP-IV (nM)</td><td>DPP-8 (μM)</td><td>DPP-9 (μM)</td><td>CYP 3A (μM)</td></tr><tr><td>7211h</td><td></td><td>10.8</td><td>>100</td><td>>100</td><td>79.36±14.78</td></tr><tr><td>7311i</td><td></td><td>6.6</td><td>>100</td><td>>100</td><td>91.93±30.21</td></tr><tr><td>7411j</td><td></td><td>2.0</td><td>>100</td><td>>100</td><td>58.28±9.47</td></tr><tr><td>7511k</td><td></td><td>9.1</td><td>>100</td><td>>100</td><td>46.24±8.07</td></tr><tr><td>76111</td><td></td><td>1.9</td><td>>100</td><td>>100</td><td>42.19±6.19</td></tr><tr><td>7711m</td><td>CI</td><td>0.36</td><td>>100</td><td>>100</td><td>46.18±6.80</td></tr><tr><td>7811n</td><td></td><td>0.68</td><td>>100</td><td>>100</td><td>54.65±7.25</td></tr><tr><td>79110</td><td>CI</td><td>1.23</td><td>>100</td><td>84.5</td><td>14.08±1.95</td></tr><tr><td>Alogliptin</td><td></td><td>1.5</td><td></td><td></td><td>>306</td></tr></table></body></html>

Data represent nominalized means of at least two independent experiments.

# 3.4.Pharmacological evaluations on compound 77.

Besides good activity and selectivity against DPP-IV,compound 77 also has low risk of drug-drug interaction and heart QT interval prolongation with $\mathrm { I C } _ { 5 0 } 4 6 . 2 \mu \mathrm { M }$ against CYP 3A and over $1 0 0 ~ \mu \mathrm { M }$ against hERG (Table 2). As regard to the in vivo evaluations,compound 77 had a fine PK profile with $7 3 . 3 \%$ bioavailability and over 5 hours half life in male rats similar tocompound70(Table 3,Figure 3).Ina 24 hours in vivo test,77 displayed lower DPP-IV activity than Alogliptin (Figure 4)and the corresponding inhibition rate were calculated in Table 4. Underour experiment condition,the half lifeof Alogliptin in malerats was close to 2 hours.Hence,77contributed to longer duration of low DPP-IV activity and slower restoration.

Table 3.Selected PK parameters for compound 77 in male Sprague Dawley Rats.   

<html><body><table><tr><td>Dose(mg/kg ) i.v./p.o.</td><td>iv T1/2 (h)</td><td>oral T1/2 (h)</td><td>poAUC0-t (μg·h·mL-1)</td><td>CLp (L·h−1·kg*1)</td><td>(L·kg-1) VzF</td><td>F%</td></tr><tr><td>5/25</td><td>5.65 ± 1.13</td><td>5.02 ± 1.39</td><td>17.58 ± 2.82</td><td>1.05 ± 0.15</td><td>8.65±2.43</td><td>73.3</td></tr></table></body></html>

i.v.,intravenous injection;p.o.,oral administration.

![](images/e642dcfd74108b9793232169ae8825857520bdc6124313b302771f524283111d.jpg)  
Figure 3.Concentration- time curve of compound 77.

![](images/fbb13b3630ffbdb3c797091861caaba245e352c8e2cfef3552768bbd7dc920bf.jpg)  
Figure 4. Effect on DPP-IV activity of compound 77 in ICR mice.

Table 4.DPP-IV inhibition of compound 77 in ICR mice.   

<html><body><table><tr><td rowspan="2"></td><td rowspan="2">Dose mg/kg</td><td colspan="3">DPP-IV inhibition</td></tr><tr><td>0.5h</td><td>4.5 h 7h</td><td>24 h</td></tr><tr><td rowspan="2">Alogliptin</td><td>3</td><td>83.80%</td><td>71.50%</td><td>50.90% 0.80%</td></tr><tr><td>1</td><td>72.60%</td><td>49.40% 27.60%</td><td>0.50%</td></tr><tr><td rowspan="2">77</td><td>3</td><td>80.40%</td><td>84.70%</td><td>82.30% 13.50%</td></tr><tr><td>1</td><td>51.80%</td><td>76.00% 71.60%</td><td>11.50%</td></tr></table></body></html>

# 4.Conclusion

Ourprevious work had demonstrated the feasibility of scaffold hopping among thienopyrimidine, pyrrolopyrimidine and pyrimidine dione in developing DPP-IV inhibitors. And replacement cyanobenzyl with butynyl was proved to be changeable in our previous work and computational structure superposition. Thus butynyl substituted pyrimidine dione compound 61 $\mathrm { I C } _ { 5 0 } { = } 1 9 8 ~ \mathrm { n M }$ ）was determined as the hit compound based on Alogliptin. Variations on N-3 position of compound 61 indicated a proper hydrophobic quinolinylmethly substitution brought better affinity with DPP-IV enzyme represented by 70 $\mathrm { T C } _ { 5 0 } { = } 3 . 1 \ \mathrm { n M }$ ).Further optimization on the quinoline ring demonstrated 7 position is the preferred substitution site.And electronic efect played an important role of quinoline part on DPP-IV inhibitory activity which might due to $\pi { - } \pi$ stacking interaction rather than steric hindrance.Eventually,in this work,the most potent and oral bioavailable DPP-IV inhibitor 77 （204号 $( \mathrm { I C } _ { 5 0 } { = } 0 . 3 6 ~ \mathrm { n M }$ $\mathrm { F } { = } 7 7 . 3 \%$ $\mathrm { T } _ { 1 / 2 } { = } 5 \mathrm { h }$ ） was proved to bear a better in vivo DPP-IV activity decrease than Alogliptin for a longer duration.

# 5.Experimental section

# 5.1. Chemistry

All commercially available compounds and solvents were of reagent grade and used without further treatment unless otherwise noted.Reactions were monitored by TLC using Qing Dao Hai Yang GF254 silica gel plates ( $_ { \textrm { \tiny 5 x } }$ $1 0 \ \mathrm { c m } ,$ ； zones were detected visually under ultraviolet irradiation（ $2 5 4 ~ \mathrm { n m } )$ and by spraying with an ethanol solution of 2,4-DNP or ninhydrin,or by fuming with iodine steam. Silica gel column chromatography was performed on silica gel (2O0-30 mesh) from Qing Dao Hai Yang.NMR spectra were recorded on a Bruker NMR AVANCE 400( ${ 4 0 0 } \mathrm { M H z } )$ ora Bruker NMR AVANCE 500( ${ 5 0 0 } \mathrm { M H z } , \$ . Chemical shifts (δ) were recorded in ppm and coupling constants (J) in hertz $\left( \mathrm { H z } \right)$ . Splitting patterns describe apparent multiplicities and are designated as s (singlet),d (doublet),t (triplet),q (quartet),m (multiplet)or br (broad).MS data were measured on an Agilent MSD-1200 ESI-MS system.

# 5.1.1.1-(but-2-yn-1-yl)-6-chloropyrimidine-2,4(1H,3H)-dione (9).

1-bromo-2-butyne ( $\mathrm { 9 . 4 ~ m L }$ , 0.11mol) was added to a mixture of 6-chloropyrimidine-2,4(1H,3H)-dione (14.6g, $0 . 1 \mathrm { m o l } \dot { } ,$ ）,ethyldiisopropylamine（15mL,0.15mol) and $2 5 0 ~ \mathrm { m L }$ of N,N-dimethylformamide.The reaction mixture is stirred overnight at ambient temperature.For working up the reaction mixture is diluted with approx. $3 0 0 ~ \mathrm { m L }$ of water.The light precipitate formed is suction filtered and washed with water.The filter cake is washed with diethyl ether and dried to give 1-(but-2-yn-1-yl)-6-chloropyrimidine-2,4(1H,3H)-dione (9)asa yellow powder ( $\mathrm { 1 7 ~ g }$ ,yield $8 5 \%$ ） $\mathrm { ^ 1 H }$ -NMR( ${ 4 0 0 } ~ \mathrm { M H z }$ $\mathrm { C D C l } _ { 3 }$ ) 8 5.91 (s,1H),4.75 (d, $J = 2 . 0 ~ \mathrm { H z }$ ,2H),1.82 (t, $J = 2 . 0 ~ \mathrm { H z }$ ,3H). ESI-MS calculated for (C8H8CIN2O2) $\mathrm { [ M + H ] } ^ { + }$ ,199.03,found 199.0.

General procedure for the synthesis of compounds10a-o.

# 5.1.2.1-(but-2-yn-1-yl)-6-chloro-3-methylpyrimidine-2,4(1H,3H)-dione (10a).

A mixture of 9 $( 5 0 0 ~ \mathrm { m g } , 2 . 5 ~ \mathrm { m m o l } )$ and $5 \mathrm { m L }$ of DMF was added NaH ( $60 \%$ in oil, 2eq) at $0 ^ { \circ } \mathrm { C }$ and LiBr(3eq) after stirred for $5 \mathrm { m i n }$ . The reaction mixture was subsequently cooled to $0 ^ { \circ } \mathrm { C }$ after stirred for $2 0 \mathrm { m i n }$ and added $\mathrm { C H } _ { 3 } \mathrm { I }$ L ${ \mathrm { 9 0 0 ~ m g } }$ ,6.2 mmol） at $0 ^ { \circ } \mathrm { C }$ 、The reaction mixture was stirred overnight at room temperature. The mixture was poured into $5 0 ~ \mathrm { m l }$ of water and extracted with ethyl acetate. The combined organic layers was washed with water and brine and dried over magnesium sulfate.After filtration the solvent is removed and the crude residue purified by silica gel column chromatography to give $5 2 5 ~ \mathrm { m g }$ $( 9 8 \% )$ of the title compound. $^ 1 \mathrm { H }$ -NMR( ${ \bf \dot { 4 0 0 } M H z }$ $\mathrm { C D C l } _ { 3 }$ 8 5.94 (s, 1H), 4.77 (d, $J = 2 . 4 ~ \mathrm { H z }$ ,2H),3.33 (s,3H),1.81-1.80 (t, $J = 2 . 4 ~ \mathrm { H z }$ ,3H).ESI-MS calculated for (C9H10CIN2O2) $\mathrm { [ M + H ] } ^ { + }$ ,213.04,found 213.0.

# 5.1.3.(R)-6-(3-aminopiperidin-1-yl)-1,3-di(but-2-yn-1-yl)pyrimidine-2,4(1H,3H)-dione (10b).

The title compound was prepared from 1-bromobut-2-yne in $9 0 . 0 \%$ yield according to the procedure for example 10a. ${ } ^ { 1 } \mathrm { H }$ -NMR(400MHz, $\mathrm { C D C l } _ { 3 }$ ) 8 5.96 (s,1H),4.80-4.78 (q, $J = 2 . 4 ~ \mathrm { H z }$ ,2H), 4.64-4.62 (q, $J = 2 . 4 ~ \mathrm { H z }$ 2H),1.82-1.81 (t, $J { = } 2 . 4 \ : \mathrm { H z }$ ,3H),1.78-1.77 (t, $J { = } 2 . 4 \ : \mathrm { H z }$ ,3H).ESI-MS calculated for(C12H12ClN2O2) $\mathrm { [ M + H ] } ^ { + }$ 251.06, found 251.0.

# 5.1.4.3-benzyl-1-(but-2-yn-1-yl)-6-chloropyrimidine-2,4(1H,3H)-dione $( I \pmb { \theta } \pmb { c } )$

The title compound was prepared from (bromomethyl)benzene in $7 6 . 0 \%$ yield according to the procedure for example 10a. $^ 1 \mathrm { H }$ -NMR（ $\mathrm { 4 0 0 M H z }$ ， $\mathrm { C D C l } _ { 3 }$ ）8 7.40-7.38 (m,2H),7.26-7.14 (m,3H),5.86 (s,1H),4.99 (s,2H), 4.65-4.64 (d, $J = 2 . 4 ~ \mathrm { H z }$ ,2H),1.73-1.72 (t, $J = 2 . 4 ~ \mathrm { H z }$ ,3H).ESI-MS calculated for (C15H14CIN2O2) $\mathrm { [ M + H ] } ^ { + }$ 289.07, found 289.1.

# 5.1.4.1-(but-2-yn--yl)-6-chloro-3-(pyrimidin-2-ylmethyl)pyrimidine-2,4(1H,3H)-dione (10d).

The title compound was prepared from 2-(chloromethyl)pyrimidine in $7 1 . 0 \%$ yield according to the procedure for example 8a. ${ } ^ { 1 } \mathrm { H }$ -NMR( ${ 4 0 0 } \mathrm { M H z }$ $\mathrm { C D C l } _ { 3 }$ )8 8.56 (d, $J { = } 4 . 8 \mathrm { H z }$ ,2H),7.09 (t, $J { = } 4 . 8 \mathrm { H z }$ ,1H),5.94 (s,1H),5.28 (s,2H),4.72-4.71 (m,2H),1.73 (t, $J = 2 . 4 ~ \mathrm { H z }$ , 3H).ESI-MS calculated for (C13H12ClN4O2) $\mathrm { [ M + H ] } ^ { + }$ ，291.06, found 291.0.

# 5.1.5.3-(1H-benzodjimidazol-2-yl)methyl)-1-(but-2-yn-1-yl)-6-chloropyrimidine-2,4(1H,3H)-dione (0e).

The title compound was prepared from 2-(chloromethyl)-1H-benzo[d]imidazole in $2 7 . 6 \%$ yield according to the procedure for example 10a. $\mathrm { ^ 1 H }$ -NMR ( $4 0 0 ~ \mathrm { { M H z } }$ $\mathrm { C D C l } _ { 3 }$ )8 7.59-7.56 (m,2H), 7.24-7.21 (m,2H),5.99 (s,1H), 5.40 (s,2H),4.75 (d, $J { = } 2 . 4 ~ \mathrm { H z }$ ,2H),1.79 (t, $J = 2 . 4 ~ \mathrm { H z }$ ,3H).ESI-MS calculated for (C16H14ClN4O2) $\mathrm { [ M + H ] } ^ { + }$

# 5.1.6.1-(but-2-yn-1-yl)-6-chloro-3-(quinolin-2-ylmethyl)pyrimidine-2,4(1H,3H)-dione (10f).

The title compound was prepared from 2-(chloromethyl)quinoline in $2 3 . 9 \%$ yield according to the procedure for example 8a. $^ 1 \mathrm { H }$ -NMR ${ \bf \Psi } _ { 4 0 0 } \bf { M H z }$ $\mathrm { C D C l } _ { 3 }$ )8 8.10 (d, $J = 8 . 4 ~ \mathrm { H z }$ ,1H),8.00 (d, $J = 8 . 4 ~ \mathrm { H z }$ ,1H), 7.77 (d, $J = 8 . 4 ~ \mathrm { H z }$ 1H),7.67-7.63 (m,1H),7.50-7.46 (m,1H),7.32 (d, $J = 8 . 4 ~ \mathrm { H z }$ ,1H),6.05 (s,1H),5.43 (s,2H),4.82-4.80 (m,2H), 1.82 (t, $J { = } 2 . 4 \ : \mathrm { H z }$ ,3H).ESI-MS calculated for(C18H15ClN3O2) $\mathrm { [ M + H ] } ^ { + }$ ,340.08,found 340.1.

# 5.1.7.3-(benzolflquinolin-3-ylmethyl)-1-(but-2-yn-1-yl)-6-chloropyrimidine-2,4(1H,3H)-dione $( I 0 g )$

The title compound was prepared from 3-(chloromethyl)benzo[flquinoline in $3 3 . 1 \%$ yield according to the procedure for example 10a. ${ } ^ { 1 } \mathrm { H } \cdot$ -NMR( ${ 4 0 0 } ~ \mathrm { M H z }$ $\mathrm { C D C l } _ { 3 }$ ) δ 8.89 (d, $J = 8 . 8 ~ \mathrm { H z }$ ,1H), 8.58 (d, $J = 8 . 0 ~ \mathrm { H z }$ ，1H), 7.95-7.90 (m,3H),7.69-7.60 (m,2H),7.49 (d, $J { = } 8 . 4 \ : \mathrm { H z }$ ,1H),6.06 (s,1H),5.48 (s,2H),4.81 (d, $J { = } 2 . 4 ~ \mathrm { H z }$ ,2H), 1.83 (t, $J { = } 2 . 4 \ : \mathrm { H z }$ ,3H).ESI-MS calculated for(C22H17ClN3O2) $\mathrm { [ M + H ] } ^ { + }$ ,390.10,found 390.1.

# 5.1.8.3-(6-bromoquinolin-2-yl)methyl)-1-(but-2-yn-1-yl)-6-chloropyrimidine-2,4(1H,3H)-dione (10h).

The title compound was prepared from 6-bromo-2-(chloromethyl)quinoline in $3 2 . 4 \%$ yield according to the procedure for example 8a. $^ 1 \mathrm { H }$ -NMR ( ${ \bf \Psi } _ { 4 0 0 } \bf { M H z }$ ， $\mathrm { C D C l } _ { 3 }$ )8 8.01 (d, $J = 8 . 8 \ \mathrm { H z }$ ,1H), 7.93 (d, $J = 2 . 0 \ \mathrm { H z }$ ,1H), 7.86 (d, $J { = } 8 . 8 \mathrm { H z }$ ,1H),7.72-7.69 (m,1H),7.34 (d, $J { = } 8 . 4 \mathrm { H z }$ ,1H),6.05 (s,1H),5.40 (s,2H),4.81-4.80 (m,2H),1.82 (t, $J { = } 2 . 4 \ : \mathrm { H z }$ ,3H).ESI-MS calculated for(C18H14BrClN3O2) $\mathrm { [ M + H ] } ^ { + }$ ,418.00,419.99,found 419.0,421.00.

# 5.1.9.1-(but-2-yn-1-yl)-6-chloro-3-((6-chloroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10i).

The title compound was prepared from 6-chloro-2-(chloromethyl)quinoline in $5 3 . 7 \%$ yield according to the procedure for example 10a. $\mathrm { ^ 1 H }$ -NMR (400 MHz, $\mathrm { C D C l } _ { 3 }$ )8 8.00 (d, $J = 8 . 4 \ : \mathrm { H z }$ ,1H), 7.92 (d, $J { = } 8 . 8 \mathrm { H z }$ ,1H), 7.74 (d, $J { = } 2 . 4 \ : \mathrm { H z }$ ,1H),7.58-7.56 (m,1H),7.34 (d, $J { = } 8 . 4 \ : \mathrm { H z }$ ,1H),6.04(s,1H),5.40 (s,2H),4.81-4.79 (m,2H),1.82 (t, $J { = } 2 . 4 \ : \mathrm { H z }$ ,3H).ESI-MS calculated for (C18H14Cl2N3O2) $\mathrm { [ M + H ] } ^ { + }$ ,374.05, 376.04, found 374.0, 376.0.

# 5.1.10. 1-(but-2-yn-1-(but-2-yn-1-yl)-6-chloro-3-(6-fluoroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10j).

The title compound was prepared from 2-(chloromethyl)-6-fluoroquinoline in $5 8 . 9 \%$ yield according to the procedure for example 10a. $^ 1 \mathrm { H }$ -NMR ( $4 0 0 ~ \mathrm { { M H z } }$ $\mathrm { C D C l } _ { 3 }$ ) δ 8.04 (d, $J = 8 . 4 ~ \mathrm { H z }$ ,1H), 7.99 (dd, $J = 5 . 2 ~ \mathrm { H z }$ ,1H), 7.44-7.34 (m,3H),6.05 (s,1H),5.41 (s,2H),4.82-4.80 (m,2H),1.82 (t, $J = 2 . 0 ~ \mathrm { H z }$ ,3H).ESI-MS calculated for (C18H14CIFN3O2) $\mathrm { [ M + H ] } ^ { + }$ ,358.08,found 358.1.

# 5.1.11.1-(but-2-yn-1-yl)-6-chloro-3-((6-methylquinolin-2-yl)methyl)pyrimidine- $2 , 4 ( I H , 3 H )$ -dione $( I O k )$

The title compound was prepared from 2-(chloromethyl)-6-methylquinoline in $5 1 . 9 \%$ yield according to the procedure for example 10a. $^ 1 \mathrm { H }$ -NMR ( $4 0 0 ~ \mathrm { { M H z } }$ $\mathrm { C D C l } _ { 3 }$ ) δ 8.01 (d, $J = 8 . 4 ~ \mathrm { H z }$ ,1H), 7.95 (d, $J = 8 . 8 ~ \mathrm { H z }$ ，1H), 7.87(d, $J = 1 . 6 \ : \mathrm { H z }$ ,1H),7.80-7.77 (m,1H),7.26(d, $J = 8 . 4 \ : \mathrm { H z }$ ,1H),5.99 (s,1H),5.25 (s,2H),4.77-4.75 (m,2H), 2.72 (s,3H),1.80 (t, $J { = } 2 . 4 \ : \mathrm { H z }$ ,3H).ESI-MS calculated for(C19H17CIN3O2) $\mathrm { [ M + H ] } ^ { + }$ ,354.10,found 354.1.

# 5.1.12.1-(but-2-yn-1-yl)-6-chloro-3-((6-methoxyquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (0l).

The title compound was prepared from 2-(chloromethyl)-6-methoxyquinoline in $5 5 . 1 \%$ yield according to the procedure for example 10a. $^ 1 \mathrm { H }$ -NMR ( $4 0 0 ~ \mathrm { { M H z } }$ $\mathrm { C D C l } _ { 3 }$ 8 7.98 (d, $J = 8 . 4 ~ \mathrm { H z }$ ,1H), 7.90 (d, $J = 9 . 2 ~ \mathrm { H z }$ ，1H), 7.31-7.27 (m,2H), 7.03 (d, $J = 2 . 8 \ \mathrm { H z }$ ,1H),6.04 (s,1H),5.39 (s,2H),4.81-4.79 (m,2H),3.90 (s,3H),1.82 (t, $J =$ $2 . 4 \mathrm { H z }$ ,3H).ESI-MS calculated for (C19H17CIN3O3) $\mathrm { [ M + H ] } ^ { + }$ ,370.10, found 370.1.

# 5.1.13.1-(but-2-yn-1-yl)-6-chloro-3-(7-chloroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (0m).

The title compound was prepared from 7-chloro-2-(chloromethyl)quinoline in $5 8 . 8 \%$ yield according to the procedure for example 10a. ${ } ^ { 1 } \mathrm { H }$ -NMR ( $4 0 0 ~ \mathrm { { M H z } }$ $\mathrm { C D C l } _ { 3 }$ ) 8 8.06 (d, $J = 8 . 4 ~ \mathrm { H z }$ ,1H),8.00 (s,1H), 7.69 (d, $J = 8 . 8$ （204号 Hz,1H), 7.43-7.41 (m,1H), 7.32 (d, $J = 8 . 4 \ : \mathrm { H z }$ ,1H),6.04 (s,1H),5.40 (s,2H),4.81-4.80 (m,2H),1.83 (t, $J = 2 . 4$ Hz,3H).ESI-MS calculated for (C18H14Cl2N3O2) $\mathrm { [ M + H ] } ^ { + }$ ,374.05,376.04,found 374.0, 376.0.

# 5.1.14.1-(but-2-yn-1-yl)-6-chloro-3-(7-fluoroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione $( I 0 n )$

The title compound was prepared from 2-(chloromethyl)-7-fluoroquinoline in $4 2 . 7 \%$ yield according to the procedure for example 10a. $\mathrm { ^ 1 H }$ -NMR ( ${ \bf \Psi } _ { 4 0 0 } \bf { M H z }$ $\mathrm { C D C l } _ { 3 }$ )8 8.08 (d, $J = 8 . 8 ~ \mathrm { H z }$ ,1H),7.77-7.73 (m,1H), 7.63-7.60 (m,1H),7.30-7.25 (m,2H),6.05 (s,1H),5.41 (s,2H),4.82-4.81 (m,2H),1.83 (t, $J = 2 . 4 ~ \mathrm { H z }$ ,3H).ESI-MS calculated for (C18H14CIFN3O2) $\mathrm { [ M + H ] } ^ { + }$ ,358.08,found 358.1.

# 5.1.15.1-(but-2-yn-1-yl)-6-chloro--(4-chloroquinolin-2-yl)methyl)pyrimidine-2,4(H,3H)-dione(0).

The title compound was prepared from 4-chloro-2-(chloromethyl)quinoline in $5 8 . 0 \%$ yield according to the procedure for example 10a. ${ } ^ { 1 } \mathrm { H } \cdot$ -NMR( ${ 4 0 0 } ~ \mathrm { M H z }$ $\mathrm { C D C l } _ { 3 }$ ) δ 8.17 (d, $J = 8 . 0 ~ \mathrm { H z }$ ,1H), 8.02 (d, $J = 8 . 4 ~ \mathrm { H z }$ ，1H), 7.72-7.68 (m,1H),7.60-7.56 (m,1H),7.41 (s,1H),6.05 (s,1H),5.39 (s,2H),4.81-4.80 (m,2H),1.82 (t, $J = 2 . 4$ Hz,3H).ESI-MS calculated for (C18H14Cl2N3O2) $\mathrm { [ M + H ] } ^ { + }$ ,374.05,376.04, found 374.0, 376.0.

General Procedure for the Synthesis of Compounds 1la-p.

# 5.1.16.(R)-6-(3-aminopiperidin-1-yl)-1-(but-2-yn-1-yl)-3-methylpyrimidine-2,4(1H,3H)-dione $( I I a )$

A mixture of10a ( $2 0 0 ~ \mathrm { m g }$ ， $0 . 9 4 \mathrm { \ m m o l }$ ）， $( R )$ -3-aminopiperdine dihydrochloride( $2 4 4 ~ \mathrm { m g }$ ，1.41 mmol）and sodium bicarbonate $3 9 5 ~ \mathrm { m g } , 4 . 7 ~ \mathrm { m m o l } ,$ ）were stirried with $1 0 0 ~ \mathrm { { m g } }$ activated MS(4A) in dry ethanol ( $\mathrm { 1 0 ~ m L }$ at $1 0 0 ^ { \circ } \mathrm { C }$ for 2h.The reaction concentrated in vacuo,and purified by flash chromatography to afford $1 6 9 \mathrm { m g } ( 6 5 . 2 \% )$ （20 of the title compound. ${ } ^ { 1 } \mathrm { H }$ -NMR ( ${ \bf \Psi } _ { 4 0 0 } \bf { M H z }$ ,MeOD)δ 5.32 (s,1H),4.67-4.57 (m,2H),3.38-3.36 (m,2H),3.32 (s, 3H),3.05-2.98 (m,1H),2.84-2.79 (m,1H),2.61-2.56 (m,1H),2.08-2.04 (m,1H),1.96-1.91(m,1H),1.87 (t, $J =$ $2 . 4 \ : \mathrm { H z }$ ,3H),1.83-1.74 (m,1H),1.44-1.35 (m,1H); ${ } ^ { 1 3 } \mathrm { C }$ -NMR( $1 2 5 \mathrm { M H z }$ ,MeOD) 8 165.41,161.55,153.75,89.32, 80.97,74.80,59.41, 52.82,48.49,36.62,33.47,28.12,24.33,3.07.ESI-MS calculated for (C14H21N4O2) $\mathrm { [ M + H ] } ^ { + }$ ,277.17,found 277.2.

# 5.1.17.(R)-6-(3-aminopiperidin-1-yl)-1,3-di(but-2-yn-1-yl)pyrimidine-2,4(1H,3H)-dione (b).

The title compound was prepared from 1,3-di(but-2-yn-1-yl)-6-chloropyrimidine-2,4(1H,3H)-dione (10b）in $6 8 . 2 \%$ yield according to the procedure for example 11a. $^ 1 \mathrm { H }$ -NMR( ${ \bf \zeta } 4 0 0 ~ \mathrm { M H z }$ ,MeOD) δ 5.32 (s, 1H), 4.47-4.58 (m,4H),3.41-3.40 (m,1H),3.37-3.36 (m,1H),3.05-2.98 (m,1H),2.86-2.81 (m,1H),2.63-2.58 (m,1H), 2.08-2.04 (m,1H),1.97-1.93 (m,1H),1.87 (t, $J = 2 . 0 ~ \mathrm { H z }$ ,3H),1.81 (t, $J = 2 . 0 ~ \mathrm { H z }$ ,3H),1.78-1.74 (m,1H), 1.45-1.35 (m, 1H); $^ { 1 3 } \mathrm { C }$ -NMR( $1 2 5 ~ \mathrm { M H z }$ ，MeOD) 8 164.15,161.83,152.98,89.32,81.17, 78.93,74.73,74.55, 59.37,52.79,48.47,36.77,33.45,31.57,24.31，3.11,3.05.ES1-MS calculated for (C17H23N4O2) $\mathrm { [ M + H ] } ^ { + }$ 315.18, found 315.2.

# 5.1.18.(R)-6-(3-aminopiperidin-1-yl)-3-benzyl-1-(but-2-yn-1-yl)pyrimidine-2,4(1H,3H)-dione (lc).

The titlecompound was prepared from 3-benzyl-1-(but-2-yn-1-yl)-6-chloropyrimidine-2,4(1H,3H)-dione(10c) in $6 7 . 0 \%$ yield according to the procedure for example 11a. $^ 1 \mathrm { H }$ -NMR( ${ 4 0 0 } ~ \mathrm { M H z }$ ,MeOD) δ 7.35-7.31 (m, 2H), 7.29-7.22 (m,3H), 5.30 (s,1H),5.07 (s,2H),4.56 (t, $J = 1 8 . 4 ~ \mathrm { H z }$ ，2H),3.37-3.33 (m,2H),2.96-2.93 (m,1H),

2.81-2.73 (m,1H),2.57-2.52 (m,1H),2.02-1.99 (m,1H),1.89-1.86 (m,1H),1.81 (s,3H),1.76-1.71(m,1H), 1.38-1.31 (m, 1H); ${ } ^ { 1 3 } \mathrm { C }$ -NMR (125 MHz,MeOD) δ 165.10,161.72,153.66,138.42,129.35(2C),129.15(2C), 128.41,89.37,81.10,74.71,59.36,52.75,48.45,45.22,36.83,33.45,24.31，3.06.ESI-MS calculated for (C20H25N4O2) $\mathrm { [ M \mathrm { + H } ] } ^ { + }$ ,353.20,found 353.2.

The title compound was prepared from 1-(but-2-yn-1-yl)-6-chloro-3-(pyrimidin-2-ylmethyl)pyrimidine-2,4(1H,3H)-dione (10d) in $6 9 . 4 \%$ yield according to the procedure for example 1la. $\mathrm { ^ 1 H }$ -NMR( ${ 4 0 0 } \mathrm { M H z }$ $\mathrm { C D C l } _ { 3 }$ 8 8.59 (d, $J { = } 4 . 8 \mathrm { H z }$ ,2H), 7.09 (t, $J { = } 4 . 8 ~ \mathrm { H z }$ ,1H), 5.32(s,2H),5.25 (s,1H),4.51 (d, $J = 2 . 0 ~ \mathrm { H z }$ ,2H),3.60-3.33 (m,1H),3.25-3.22 (m,1H),3.01-2.97 (m,1H), 2.73-2.71 (m,1H),2.55-2.45 (m,1H),1.97-1.93 (m,1H),1.86-1.82 (m,1H),1.76 (s,3H),1.68-1.60 (m,1H), 1.30-1.25 (m, 1H); $^ { 1 3 } \mathrm { C } .$ -NMR( ${ 1 2 5 } \mathrm { M H z }$ ， $\mathrm { C D C l } _ { 3 }$ )8 165.36,163.07,159.52,157.17,152.26,119.30,89.04,80.25, 73.64,56.72,51.65,47.50,46.10,35.78,31.07,22.94,3.63;ES1-MS calculated for (C18H23N6O2) $\mathrm { [ M + H ] } ^ { + }$ 355.19, found 355.2.

# 5.1.20.(R)-3-(1H-benzodimidazol-2-yl)methyl)-6-(3-aminopiperidin-1-yl)--(but-2-yn--yl)pyrimidine-2,4(1H, 3H)-dione (1le).

The title compound was prepared from 3-(1H-benzo[dJimidazol-2-yl)methyl)-1-(but-2-yn-1-yl)-6-chloropyrimidine-2,4(1H3H)-dione(10e）in $3 5 . 1 \%$ yield according to the procedure for example 11a. $^ 1 \mathrm { H }$ -NMR( ${ \bf \Psi } _ { 4 0 0 } \bf { M H z }$ $\mathrm { C D C l } _ { 3 }$ )8 7.57-7.41 (m,2H), 7.19-1.12 (m, 2H),5.31 (s,2H),5.18(s,1H),4.40 (s,2H),3.22-3.19 (m,3H),3.01-2.95 (m,1H),2.66-2.59 (m,1H),2.46-2.40 (m，1H)，1.98-1.88 (m，1H)，1.75 (s,3H)，1.64-1.55 (m,1H)，1.32-1.26 (m,1H); ${ } ^ { 1 3 } \mathrm { C } .$ -NMR (125MHz, $\mathrm { C D C l _ { 3 } + M e O H }$ )8 162.87,159.64,151.96,149.77,137.81,122.36,114.73,88.57,80.37,73.26,56.36,51.30,49.82, 47.13,35.71,30.82,22.63,3.25;ESI-MS calculated for (C21H25N6O2) $[ \mathrm { M } \mathrm { + H } ] ^ { + }$ ,393.20, found 393.20.

# 5.1.21.(R)-6-(3-aminopiperidin-1-yl)--(but-2-yn-1-yl)-3-(quinolin-2-ylmethyl)pyrimidine-2,4(1H,3H)-dione (11f).

The title compound was prepared from 1-(but-2-yn-1-yl)-6-chloro-3-(quinolin-2-ylmethyl)pyrimidine-2,4(1H,3H)-dione (10f) in $8 9 . 7 \%$ yield according to the procedure for example 11a. $^ 1 \mathrm { H }$ -NMR( ${ 4 0 0 } \mathrm { M H z }$ $\mathrm { C D C l } _ { 3 }$ )8 8.05 (d, $J = 8 . 8$ Hz,1H), 8.00 (d, $J = 8 . 8 ~ \mathrm { H z }$ ,1H), 7.73 (d, $J = 8 . 0 ~ \mathrm { H z }$ ,1H),7.62 (t, $J = 7 . 2 ~ \mathrm { H z }$ ,1H), 7.44 (t, $J { = } 7 . 2 ~ \mathrm { H z }$ ,1H),7.29 (t, $J = 8 . 4 ~ \mathrm { H z }$ ,1H),5.40 (s,2H), 5.28 (s,1H),4.53 (d, $J { = } 2 . 4 \ : \mathrm { H z }$ ,2H),3.35-3.32 (m,1H),3.24-3.21 (m,1H),3.02-2.98 (m,1H),2.73-2.71 (m,1H), 2.55-2.46 (m,1H),1.97-1.93 (m,1H),1.79-1.76 (m,1H),1.72 (s,3H),1.71-1.61 (m,1H),1.31-1.23 (m,1H); ${ } ^ { 1 3 } \mathrm { C }$ -NMR ( ${ 1 2 5 ~ \mathrm { M H z } }$ $\mathrm { C D C l } _ { 3 }$ )8 163.04,159.51,156.49,152.39,147.65,136.56,129.26,129.21,127.37,127.25, 126.02,119.09,89.05,80.15,73.68,58.42,51.48,47.47,46.47,35.65,32.44,23.09,3.59; ES1-MS calculated for (C23H26N5O2) $\mathrm { [ M \mathrm { + H } ] } ^ { + }$ ,404.21,found 404.2.

# 5.1.22.(R)-6-(3-aminopiperidin--yl)-3-(benzolflquinolin-3-ylmethyl)--(but-2-yn-1-yl)pyrimidine-2,4(1H,H)- ione $( I I g )$

The title compound was prepared from 3-(benzo[flquinolin-3-ylmethyl)-1-(but-2-yn-1-yl)-6-chloropyrimidine-2,4(1H,3H)-dione $( \bf { 1 0 9 } )$ in $8 5 . 8 \%$ yield according to the procedure for example 11a. $^ 1 \mathrm { H }$ -NMR( $4 0 0 ~ \mathrm { { M H z } }$ $\mathrm { C D C l } _ { 3 }$ )8 8.77 (d, $J = 8 . 8 \ \mathrm { H z }$ ,1H), 8.46 (d, $J =$ $8 . 0 \mathrm { H z }$ ,1H),7.88-7.80 (m,3H),7.58-7.50 (m,2H),7.41(d, $J { = } 8 . 4 \ : \mathrm { H z }$ ,1H),5.44 (s,2H),5.24 (s,1H),4.48 (d, $J =$

2.0 Hz,2H),3.26-3.23 (m,1H),3.17-3.14 (m,1H),2.92-2.87 (m,1H),2.64-2.59 (m,1H),2.43-2.39 (m,1H), 1.88-1.84 (m,1H),1.77-1.76 (m,1H),1.73 (s,3H),1.62-1.53 (m,1H),1.22-1.16 (m,1H); $^ { 1 3 } \mathrm { C }$ -NMR ( ${ 1 2 5 ~ \mathrm { M H z } }$ ， CDCl)8 163.08,159.48,156.06,152.35,147.63,131.46,131.25,130.58,129.51,128.53,128.19,126.90,124.15, 122.47,119.13,89.05,80.19,73.66,57.83,51.51,47.46,46.29,35.70,31.98,23.02,3.61;ES1-MS calculated for (C27H28N5O2) $\mathrm { [ M \mathrm { + H } ] } ^ { + }$ ,454.22, found 454.2.

# 5.1.23.(R)-6-(3-aminpiperidin--yl)-3-(-bromoquinolin-2-yl)methyl)--(but-2-yn-1-yl)pyrimidine-2,4(1H3H) -dione (llh).

The title compound was prepared from 3-(6-bromoquinolin-2-yl)methyl)-1-(but-2-yn-1-yl)-6-chloropyrimidine-2,4(1H,3H)-dione (10h）in $8 6 . 3 \%$ yield according to the procedure for example 11a. $^ 1 \mathrm { H }$ -NMR( ${ 4 0 0 } \mathrm { M H z }$ $\mathrm { C D C l } _ { 3 }$ )8 7.95 (d, $J { = } 8 . 8 \mathrm { H z }$ ,1H), 7.88-7.84 (m, 2H), 7.68-7.65 (m,1H), 7.31 (d, $J = 8 . 4 \ : \mathrm { H z }$ ,1H),5.37 (s,2H),5.28 (s,1H),4.54 (d, $J { = } 2 . 4 \ : \mathrm { H z }$ ,2H), 3.36-3.34 (m, 1H),3.25-3.22 (m,1H),3.04-2.98 (m,1H),2.75-2.70 (m,1H),2.54-2.51(m,1H),1.98-1.94(m,1H),1.88-1.83(m, 1H), 1.77 (t, $J = 2 . 4 ~ \mathrm { H z }$ ,3H),1.74-1.64 (m,1H),1.33-1.27 (m,1H); ${ } ^ { 1 3 } \mathrm { C }$ -NMR( $1 2 5 ~ \mathrm { M H z }$ ， $\mathrm { C D C l } _ { 3 }$ ）8162.99, 159.51,156.92,152.23,146.03,135.50,132.58,130.79,129.31,128.22,119.99,119.70,88.83,80.14,73.55, 57.58,51.43,47.36,46.25,35.68,31.77,22.91,3.52;ES1-MS calculated for (C23H25BrN5O2) $\mathrm { [ M + H ] } ^ { + }$ ，482.12, 484.12, found 482.1, 484.1.

# 5.1.24.(R)-6-(3-minopiperidin-1-yl)--(but-2-yn-1-yl)-3-(6-chloroquinolin-2-yl)methyl)pyrimidine-2,4(H,H) -dione $( I I i )$

The title compound was prepared from 1-(but-2-yn-1-yl)-6-chloro-3-(6-chloroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10i) in $8 2 . 9 \%$ yield according to the procedure for example 1la. $^ 1 \mathrm { H }$ -NMR (400 MHz, $\mathrm { C D C l } _ { 3 }$ )8 7.95 (d, $J = 8 . 8 \ \mathrm { H z }$ ,1H),7.91 (d, $J =$ $8 . 8 \ : \mathrm { H z }$ ,1H),7.70 (d, $J = 2 . 4 ~ \mathrm { H z }$ ，1H),7.55-7.52 (m,1H),7.30 (d, $J = 8 . 4 ~ \mathrm { H z }$ ，1H),5.37 (s,2H),5.28 (s,1H),4.53 (d, $J = 2 . 4 ~ \mathrm { H z }$ ,2H),3.35-3.32 (m,1H),3.24-3.21 (m,1H),3.03-2.97 (m,1H),2.74-2.69 (m,1H),2.53-2.50 (m, 1H),1.97-1.93 (m,1H),1.87-1.82 (m,1H),1.76 (t, $J = 2 . 4 ~ \mathrm { H z }$ ,3H),1.71-1.64 (m,1H),1.31-1.26 (m,1H); ${ } ^ { 1 3 } \mathrm { C }$ -NMR ( $1 2 5 ~ \mathrm { M H z }$ $\mathrm { C D C l } _ { 3 }$ )8 162.98,159.44,156.71,152.15,145.76,135.57,131.50,130.59,130.00,127.64, 125.91,119.96,88.76,80.11,73.49,57.06,51.40,47.29,46.17,35.67,31.34,22.82,3.47;ES1-MS calculated for (C23H25CIN502) $\mathrm { [ M + H ] } ^ { + }$ ,438.17,found 438.2.

# 5.1.25.(R)-6-(-aminopiperidin--y)--(but-2-yn--y)-3-(6-fluoroqinolin-2-yl)methy)pyrimidine-2,4(H,H) dione $( I I j )$

The title compound was prepared from 1-(but-2-yn-1-yl)-6-chloro-3-(6-fluoroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10j）in $8 8 . 1 \%$ yield according to the procedure for example 11a. ${ } ^ { 1 } \mathrm { H }$ -NMR( ${ 4 0 0 } \mathrm { M H z }$ $\mathrm { C D C l } _ { 3 }$ )8 7.99-7.96 (m,2H),7.40-7.29 (m, 3H), 5.37 (s,2H), 5.28 (s,1H),4.53 (d, $J = 2 . 4 ~ \mathrm { H z }$ ,2H),3.35-3.32 (m,1H),3.24-3.21 (m,1H),3.03-2.98 (m,1H), 2.73-2.68 (m,1H),2.52-2.50 (m,1H),1.97-1.93 (m,1H),1.87-1.82 (m,1H),1.77 (t, $J { = } 2 . 0 \mathrm { H z }$ ,3H),1.71-1.61 (m, 1H), 1.31-1.26 (m, 1H); $^ { 1 3 } \mathrm { C } .$ -NMR( ${ 1 2 5 ~ \mathrm { M H z } }$ $\mathrm { C D C l _ { 3 } + M e O H }$ )8 163.12,159.99,159.52,155.65,152.15,144.30, 136.11,131.02,127.67,119.74,119.43,110.30,88.76,80.22,73.26,57.17,51.42,47.18,46.04,35.57,31.41, 22.76,3.27; ESI-MS calculated for (C23H25FN5O2) $\mathrm { [ M + H ] } ^ { + }$ ,422.20, found 422.2.

# 5.1.26.(R)-6-(3-aminopiperidin--yl)-1-(but-2-yn--yl)-3-(-methylquinolin-2-yl)methyl)pyrimidine-2,4(,H) -dione (1lk).

The title compound was prepared from

1-(but-2-yn-1-yl)-6-chloro-3-((6-methylquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10k)in $8 2 . 1 \%$ yield according to the procedure for example 11a. ${ } ^ { 1 } \mathrm { H }$ -NMR( ${ \bf \Psi } _ { \mathrm { 4 0 0 M H z } }$ $\mathrm { C D C l } _ { 3 }$ )8 7.98 (d, $J { = } 8 . 4 \ : \mathrm { H z }$ ,1H), 7.92-7.87 (m, 2H),7.82-7.79 (m,1H), 7.21 (d, $J = 8 . 4 ~ \mathrm { H z }$ ,1H),5.23-5.22 (m, 3H),4.49 (d, $J = 1 . 2 ~ \mathrm { H z }$ ,2H),3.31-3.28 (m,1H), 3.20-3.17 (m,1H),3.01-2.94 (m,1H),2.68 (s,3H),2.48-2.46 (m,1H),1.96-1.92 (m,1H),1.85-1.80 (m,1H),1.78 (t, $J = 2 . 4 ~ \mathrm { H z }$ ,3H),1.71-1.59 (m,2H),1.29-1.27 (m,1H); ${ } ^ { 1 3 } \mathrm { C }$ -NMR( $1 2 5 ~ \mathrm { M H z }$ $\mathrm { C D C l } _ { 3 }$ )8 162.86,159.23,158.70, 152.02,146.98,136.11,134.27,130.53,128.27,127.65,125.98,121.87,88.83,80.14,73.48,57.97,51.29,47.29, 43.98,35.52,32.08,25.04,22.91,3.47; ESI-MS calculated for (C24H28N5O2) $\mathrm { [ M + H ] } ^ { + }$ ,418.22, found 418.2.

# 5.1.29.(R)-6-(3-aminopiperidin-1-yl)-1-(but--yn-1-yl)--(6-methoxyquinolin-2-yl)methyl)pyrimidine-,4(1H,3 H)-dione (1ll).

The title compound was prepared from 1-(but-2-yn-1-yl)-6-chloro-3-((6-methoxyquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10l) in $8 8 . 4 \%$ yield according to the procedure for example 11a. $^ 1 \mathrm { H }$ -NMR ${ \bf \Psi } _ { 4 0 0 } \bf { M H z }$ $\mathrm { C D C l } _ { 3 }$ )8 7.94 (d, $J = 8 . 4 ~ \mathrm { H z }$ ,1H),7.89 (d, $J =$ 9.2 Hz,1H),7.28-7.24 (m,2H),7.00 (d, $J = 2 . 4 ~ \mathrm { H z }$ ,1H),5.37 (s,2H),5.28 (s,1H),4.53 (d, $J = 1 . 6 \ : \mathrm { H z }$ ,2H), 3.86 (s,3H),3.34-3.32(m,1H),3.24-3.21(m,1H),3.03-2.99 (m,1H),2.73-2.68 (m,1H),2.53-2.50(m,1H),1.98-1.94 (m,1H),1.86-1.83 (m,1H),1.78 (s,3H),1.69-1.65 (m,1H),1.29-1.27 (m,1H); ${ } ^ { 1 3 } \mathrm { C } .$ -NMR( $1 2 5 ~ \mathrm { M H z }$ ， $\mathrm { C D C l } _ { 3 }$ 8 163.06,159.39,157.35,153.88,152.29,143.63,135.34,130.48,128.13,121.84,119.42,104.93,88.97,80.11, 73.63,57.47,55.36,51.46,47.39,46.27,35.65,31.68,22.94,3.55；ESI-MS calculated for (C24H28N503) （204号 $\mathrm { [ M + H ] } ^ { + }$ ,434.22,found 434.2.

# 5.1.28.(R)--(3-aminopiperidin-1-yl)--(but-2-yn-1-yl)-3-(7-chloroquinolin-2-yl)methyl)pyrimidine-2,4(,H) -dione $( I I m )$

The title compound was prepared from 1-(but-2-yn-1-yl)-6-chloro-3-((7-chloroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione $\mathbf { ( 1 0 m ) }$ in $6 6 . 4 \%$ yield according to the procedure for example 1la. $^ 1 \mathrm { H }$ -NMR( ${ \bf \dot { 4 0 0 M H z } }$ $\mathrm { C D C l } _ { 3 }$ )8 8.03 (d, $J { = } 8 . 4 ~ \mathrm { H z }$ ,1H), 7.99 (s,1H), 7.67 (d, $J { = } 8 . 4 \ : \mathrm { H z }$ ,1H),7.41-7.39 (m,1H),7.30 (d, $J { = } 8 . 4 \ : \mathrm { H z }$ ,1H),5.39 (s,2H),5.30 (s,1H),4.56 (d, $J { = } 2 . 0 \mathrm { H z }$ 2H),3.38-3.36 (m,1H),3.27-3.24 (m,1H),3.06-3.02 (m,1H),2.77-2.72 (m,1H),2.56-2.54 (m,1H),1.99-1.96 (m, 1H),1.90-1.86 (m,1H),1.79 (s,3H),1.75-1.70 (m,1H),1.34-1.29 (m,1H); $^ { 1 3 } \mathrm { C }$ -NMR( $1 2 5 ~ \mathrm { M H z }$ ， $\mathrm { C D C l } _ { 3 }$ 8 162.97,159.53,157.48,152.35,147.94,136.27,134.96,128.57,128.25,126.97,125.56,119.40,88.96, 80.13, 73.62,58.45,51.47,47.44,46.16,35.61,32.47,23.07,3.55;ES1-MS calculated for (C23H25CIN5O2) $\mathrm { [ M + H ] } ^ { + }$ 438.17, found 438.2.

# 5.1.29.(R)-6-(-aminopiperidin--y)--(but-2-yn--y)-3-(7-fluoroquinolin-2-yl)methyl)pyrimidine-2,4(H,H) dione (lln).

The title compound was prepared from 1-(but-2-yn-1-yl)-6-chloro-3-(7-fluoroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10n）in $9 2 . 5 \%$ yield according to the procedure for example 11a. ${ } ^ { 1 } \mathrm { H }$ -NMR ${ \bf \Psi } _ { \mathrm { 4 0 0 M H z } }$ $\mathrm { C D C l } _ { 3 }$ 8 8.05 (d, $J { = } 8 . 8 \mathrm { H z }$ ,1H),7.75-7.71 (m, 1H),7.64-7.61 (m,1H),7.28-7.22 (m,2H),5.40 (s,2H),5.31 (s,1H),4.56 (d, $J { = } 1 . 6 \mathrm { H z }$ ,2H),3.38-3.36 (m, 1H), 3.27-3.24 (m,1H),3.06-3.02 (m,1H),2.77-2.72 (m,1H),2.56-2.54 (m,1H),2.00-1.97(m,1H),1.90-1.86 (m,1H), 1.80 (s,3H),1.75-1.72 (m,1H),1.34-1.29 (m,1H); ${ } ^ { 1 3 } \mathrm { C }$ -NMR( $1 2 5 \mathrm { M H z }$ $\mathrm { C D C l } _ { 3 }$ )8 162.96,162.85,159.50,157.52, 152.30,148.52,136.36,129.31,124.16,118.40,116.35,112.80,88.91,80.10,73.59,58.11,51.44,47.40,46.22, 35.61,32.19,23.00,3.51;ESI-MS calculated for (C23H25FN5O2) $\mathrm { [ M + H ] } ^ { + }$ ,422.20,found 422.2.

# 5.1.30.(R)-6-(3-aminopiperidin--yl)--(but-2-yn--yl)-3-(4-chloroquinolin-2-yl)methyl)pyrimidine-2,4(,H)

# -dione $( I I o )$

The title compound was prepared from 1-(but-2-yn-1-yl)-6-chloro-3-(4-chloroquinolin-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione (10o）in $7 1 . 9 \%$ yield according to the procedure for example 11a. $^ 1 \mathrm { H }$ -NMR( $4 0 0 ~ \mathrm { { M H z } }$ $\mathrm { C D C l } _ { 3 }$ )88.13 (d, $J = 8 . 4 ~ \mathrm { H z }$ ,1H),8.02 (d, $J =$ $8 . 4 \ : \mathrm { H z }$ ,1H),7.68(t, $J { = } 7 . 6 \mathrm { H z }$ ,1H),7.55 (t, $J { = } 7 . 6 \mathrm { H z }$ ,1H),7.38 (s,1H),5.37 (s,2H),5.30 (s,1H),4.55 (s,2H), 3.38-3.35 (m,1H),3.26-3.24 (m,1H),3.08-2.97(m,1H),2.82-2.67 (m,1H),2.60-2.47(m,1H),1.98-1.96 (m,1H), 1.88-1.87 (m,1H),1.79 (s,3H),1.75-1.65 (m,1H),1.34-1.26 (m,1H); $^ { 1 3 } \mathrm { C }$ -NMR( ${ 1 2 5 ~ \mathrm { M H z } }$ ， $\mathrm { C D C l } _ { 3 }$ 8 162.87, 159.59,156.62,152.35,148.49,142.98,130.19,129.63,127.05,125.47,123.80,119.16,89.01,80.28,73.58, 58.68,51.49,47.49,46.22,35.72,32.66,23.12,14.06,3.60; ESI-MS calculated for(C23H25CIN5O2) $\mathrm { [ M + H ] } ^ { + }$ ， 438.17, found 438.17.

# 5.2.In vitro inhibitionofDPP-IV,DPP-8 and DPP-9

Solutions of test compounds at varying concentrations $( { \le } 1 0 \ \mathrm { m M }$ final concentration） were prepared in dimethyl sulfoxide(DMSO） and diluted into assay buffer containing $2 0 ~ \mathrm { m M }$ Tris $\mathrm { ( p H ~ 7 . 4 ) }$ ， $2 0 ~ \mathrm { m M }$ KCl,and $0 . 1 \mathrm { m g / m L }$ BSA.Human DPP-IV $\mathrm { { [ 0 . 1 \ n M } }$ final concentration） was added to the dilutions and pre-incubated for 10 minutesat ambient temperature before the reaction was initiated by the addition of Gly-Pro-AMC (H-glycyl-prolyl-7-amino-4-methylcoumarin, Sigma-Aldrich, $1 0 \mu \mathrm { M }$ final concentration). The total volume of the reaction mixture was $1 0 0 ~ \mu \mathrm { L }$ .The kinetics of the reaction was monitored (excitation at $4 0 0 ~ \mathrm { { n m } }$ ,emission at 505 nm) for 5-1O minutes,or an endpoint was measured after 1O minutes.Inhibition constants $( \mathrm { I C } _ { 5 0 } )$ were calculated from enzyme progress curves using standard mathematical models.

# 5.3In vivo pharmacokinetic study

Adult male SD rats $( \mathrm { { n } = 4 / g r o u p ) }$ were administered the test compounds dissolved in distilled water at a single dose of $2 0 ~ \mathrm { m g / k g }$ or $2 5 ~ \mathrm { m g / k g }$ for oral administration and $5 ~ \mathrm { m g / m L }$ by injection. Blood samples of $1 0 0 { - } 2 0 0 ~ \mu \mathrm { L }$ were collected from the orbit at11 time points within 24 hours.The blood concentration of test compounds was determined by LC-MS/MS.The PK parameters were obtained from the pharmacokinetic software DAS.2.0.

# Acknowledgement

This research was supported by Grant No.2Oo9Z1-E871 from the Bureau of Science and Technology of Guangzhou Municipality and the Natural Science Foundation of China (NSFC 21102145).

# Referencesand notes

1.Hollander,P.A.; Kushner,P.,Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors.Postgrad Med 2010,122 (3),71-80.   
2. Ahren,B.,DPP-4 inhibitors.Best Pract Res Clin Endocrinol Metab 2007,21(4),517-33.   
3. (a)Kim,D.;Wang,L.;Beconi,M.;Eiermann,GJ.;Fisher,M.H.; He,H.; Hickey,GJ.; Kowalchick,J.E.; Leiting,B.; Lyons,K.; Marsilio,F.; McCann,M.E.;Patel,R.A.;Petrov,A.; Scapin,G;Patel,.B.;Roy,R.S.; Wu,J. K.；Wyvratt, M.J.；Zhang，B.B.；Zhu，L.； Thornberry,N.A.;Weber，A.E., (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin   
-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:a potent,orallactive dipeptidyl peptidase IVinhibitor forthe treatment of type2diabetes.JMed Chem 2005,48(1),141-51;(b)Kim,D.; Kowalchick,J.E.; Brockunier,L.L.; Parmee,E.R.;Eiermann, GJ.; Fisher,M.H.; He,H.; Leiting,B.; Lyons, K.; Scapin, G; Patel, S.B.; Petrov,A.; Pryor, K.D.; Roy,R.S.; Wu,J.K.; Zhang,X.; Wyvrat,M.J.; Zhang,B.B.; Zhu,L.; Thornberry,N.A.; Weber,A. E.,Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.JMed Chem 2008,51 (3),589-602.   
4.(a) Villhauer,E.B.; Brinkman,J. A.; Naderi, G B.; Dunning,B.E.; Mangold,B.L.; Mone,M.D.; Russell, M.E.;Weldon,S.C.; Hughes,T.E.,1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrolidinecarbon itrile:a potent，selective，and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.JMed Chem2002,45(12),2362-5; (b)Bosi,E.; Camisasca,R.P.; Collober,C.;Rochote,E.; Garber, A.J.,Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.Diabetescare 20o7,30(4),890-5; (c)Fonseca,V.; Schweizer,A.; Albrecht,D.; Baron, M. A.; Chang,I.; Dejager, S.,Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007,50 (6), 1148-55.   
5.Augeri, D.J.; Robl,J.A.; Betebenner, D.A.; Magnin,D.R.; Khanna,A.;Robertson,J. G.； Wang,A.; Simpkins,L.M.; Taunk,P.; Huang,Q.; Han,S.P.; Abboa-Offei,B.; Cap,M.; Xin,L.; Tao,L.; Tozzo,E.; Welzel, G E.; Egan,D.M.; Marcinkeviciene,J.; Chang,S.Y.; Biler, S.A.; Kirby,M.S.; Parker,R.A.; Hamann,L. G, Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent,long-acting，orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of medicinal chemistry 20o5,48 (15), 5025-37.   
6.Feng,J.; Zhang,Z.; Wallace,M.B.; Staford,J. A.; Kaldor, S.W.; Kassel,D.B.; Navre,M.; Shi,L.; Skene, R. J.; Asakawa, T.; Takeuchi,K.; Xu,R.; Webb,D.R.; Gwaltney,S.L.,2nd, Discovery of alogliptin: a potent, selective,bioavailable,and eficacious inhibitorof dipeptidyl peptidase IV.JMed Chem20o7,50(10),2297-300. 7.Eckhardt, M.; Langkop,E.; Mark, M.; Tadayyon, M.; Thomas,L.; Nar,H.; Pfrengle, W.; Guth,B.; Lotz,R.; Sieger, P.； Fuchs, H.; Himmelsbach, F., 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-d ione (BI1356),a highly potent,selective,long-acting,and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry 2007,50 (26), 6450-6453.   
8.Noh, Y. H.; Lim,H.S.; Jin,S.J.; Kim, M.J.; Kim, Y. H.; Sung,H.R.; Choi, H.Y.; Bae, K.S.,Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin,a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunters.Clinical therapeutics 2012,34 (5), 1182-94.   
9. Yoshida,T.;Akahoshi,F.; Sakashita,H.; Kitajima,H.; Nakamura,M.; Sonda,S.; Takeuchi,M.; Tanaka,Y.; Ueda,N.; Sekiguchi,S.; Ishige,T.； Shima, K.; Nabeno,M.; Abe,Y.； Anabuki,J.; Soejima,A.; Yoshida,K.; Takashina,Y.; Ihi,S.; Kiuchi,S.;Fukuda,S.; Tsutsumiuchi,R.; Kosaka,K.; Murozono,T.; Nakamaru,Y.; Utsumi, H.；Masutomi,N.;Kishida,H.；Miyaguchi,I.; Hayashi, Y.,Discovery and preclinical profile of teneligliptin (3-[(2S,S)-4-[4-(3-methyl-1-pheny-1H-pyrazol-5-yl)piperazin--yllpyrrolidin-2-ylcarbonyl]thiazolidine):a highly potent,selective,long-lasting and orall active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorganic & medicinal chemistry 2012,20 (19),5705-19.   
10.(a)Abel,T.; Feher,J.,[Anew therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)]. Orv Hetil 2010,151(25),012-6; (b)Deacon,C.F.; Holst,J.J.; Car,R.D.,Glucagon-like peptide-1: abasis fornew approaches to the management of diabetes.Drugs Today (Barc)1999,35(3),159-70; (c) Gallwitz,B.,[Diabetes therapy--novel drugs to come (DPP-4 inhibitors,GLP-1 agonists,SGLT-2 inhibitors)1. MMWFortschr Med 2010, 152 (20), 43-4.   
11. (a)Deng,J.; Peng,L.; Zhang,G;Lan,X.; Li,C.; Chen,F.; Zhou,Y.; Lin,Z.; Chen,L.; Dai,R.; Xu,H.; Yang, L.； Zhang，X.；Hu，W.， The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type2 diabetes. European journal of medicinal chemistry 20l1, 46 (1), 71-6;(b) Xie, H.; Zeng,L.; Zeng,S.; Lu, X.; Zhang, G; Zhao,X.; Cheng, N.; Tu, Z.; Li, Z.; Xu, H.; Yang,L.; Zhang,X.; Huang,M.; Zhao, J.; Hu, W., Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. European journal of medicinal chemistry 2012, 52,205-12.   
12.Zeng, S.; Xie,H.; Zeng,L. L.; Lu, X.; Zhao, X.; Zhang, G C.; Tu,Z. C.; Xu, H.J.; Yang,L.; Zhang, X. Q.; Hu，W.，Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization. Bioorganic & medicinal chemistry 2013,21 (7),1749-55. 13．Thomas，L.；Eckhardt，M.；Langkopf,E.；Tadayyon，M.；Himmelsbach，F.；Mark，M., (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm   
ethyl)-3,7-dihydro-purine-2,6-dione (BI1356),a novel xanthine-based dipeptidyl peptidase 4 inhibitor,hasa superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.The Journal ofpharmacology and experimental therapeutics 20o8,325(1),175-82.   
14.(a)Pei,Z.，From the bench to the bedside:dipeptidyl peptidase IV inhibitors，a new class of oral antihyperglycemic agents.Current opinion in drug discovery & development 2008,1l(4),512-32; (b)Wiedeman, P.E.,DPPIV inhibition: promising therapy for the treatment of type 2 diabetes. Progress in medicinal chemistry 2007,45,63-109; (c) Green,B.D.; Flatt,P.R.; Bailey,C.J.,Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes. Expert opinion on emerging drugs 2006,1l (3),525-39.